# Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

> **NCT06032000** · PHASE1 · COMPLETED · sponsor: **Lemonex** · enrollment: 20 (actual)

## Conditions studied

- COVID-19 Infection
- COVID-19 Vaccine Adverse Reaction

## Interventions

- **BIOLOGICAL:** LEM-mR203
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06032000
- **Lead sponsor:** Lemonex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06032000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06032000, "Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06032000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*